ArticleInfection & chemotherapy2025
Clinical and Economic Outcomes Associated with Complicated Urinary Tract Infections Caused by Carbapenem-resistant
Article in Infection & chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prevalence of Carbapenem-Resistant Gram-Negative Bacilli from Intensive Care Units from Latin America and the Caribbean: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2026Review
- Clinical Characteristics and Risk Factors of Carbapenem-ResistantInfection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrinary tract infections (UTIs) affect 150 million people annually, with increased incidence among individuals over 60 years of age. Complicated UTIs (cUTIs), frequently caused by multidrug-resistant pathogens such as MATERIALS AND
methodsThis retrospective cohort study included 200 patients with cUTI admitted to the emergency department. Patients were categorized into two groups: those with CRE-cUTI and those with CSE-cUTI. Data were collected from electronic medical records, including demographics, comorbidities, antimicrobial treatments, and clinical outcomes, with a primary focus on the 30-day mortality. Kaplan-Meier survival curves, log-rank tests, and generalized linear models were used to assess mortality risk factors. Adjusted relative risks (aRRs) were reported with 95% confidence intervals (CI). The final multivariate model was adjusted for three variables selected based on epidemiological relevance: carbapenem resistance, septic shock on admission, and Charlson comorbidity index. Hospitalization costs were calculated based on the hospital's fee schedule, whereas antibiotic costs were estimated by multiplying the unit cost of each antimicrobial by the total number of vials used for cUTI treatment.
resultsTwenty-one patients with CRE-cUTI and 179 with CSE-cUTI were enrolled. Third-generation cephalosporins and carbapenems were the most frequently used empirical antibiotics. Inappropriate empirical therapy was higher in the CRE group (76.2%
conclusionPatients with cUTI caused by CRE experienced significantly higher 30-day mortality and hospital costs than those with cUTI caused by CSE. Effective prevention and management strategies are crucial to improve outcomes and reduce the economic burden of CRE-cUTIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.